Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/286296
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Pharmacological strategies for post-traumatic stress disorder (PTSD): From animal to clinical studies |
Autor: | Gasparyan, Ani CSIC ORCID; Navarro, Daniela CSIC ORCID; Navarrete, Francisco CSIC ORCID; Manzanares, Jorge CSIC ORCID CVN | Fecha de publicación: | 2022 | Editor: | Elsevier | Citación: | Neuropharmacology 218: 109211 (2022) | Resumen: | Post-traumatic stress disorder (PTSD) is a disabling psychiatric condition with a critical familiar, personal, and social impact. Patients diagnosed with PTSD show various symptoms, including anxiety, depression, psychotic episodes, and sleep disturbances, complicating their therapeutic management. Only sertraline and paroxetine, two selective serotonin reuptake inhibitors, are approved by different international agencies to treat PTSD. In addition, these drugs are generally combined with psychotherapy to achieve positive results. However, these pharmacological strategies present limited efficacy. Nearly half of the PTSD patients do not experience remission of symptoms, possibly due to the high prevalence of psychiatric comorbidities. Therefore, in clinical practice, other off-label medications are common, even though the effectiveness of these drugs needs to be further investigated. In this line, antipsychotics, antiepileptics, adrenergic blockers, benzodiazepines, and other emerging pharmacological agents have aroused interest as potential therapeutic tools to improve some specific symptoms of PTSD. Thus, this review is focused on the most widely used drugs for the pharmacological treatment of PTSD with a translational approach, including clinical and preclinical studies, to emphasize the need to develop safer and more effective medications. | Descripción: | This article is part of the Special Issue on ‘Fear, anxiety and PTSD’. | Versión del editor: | https://doi.org/10.1016/j.neuropharm.2022.109211 | URI: | http://hdl.handle.net/10261/286296 | DOI: | 10.1016/j.neuropharm.2022.109211 | ISSN: | 0028-3908 |
Aparece en las colecciones: | (IN) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 59,24 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
5
checked on 23-abr-2024
SCOPUSTM
Citations
10
checked on 23-abr-2024
WEB OF SCIENCETM
Citations
9
checked on 24-feb-2024
Page view(s)
35
checked on 27-abr-2024
Download(s)
7
checked on 27-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.